Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Trial details
- Registry ID
- NCT07623668
- Phase
- Phase 3
The FDA approved Methylprednisolone on 24 Oct 1957.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation ResearchNCT07623668 | Oculis | Phase 3 | Recruiting | 2027-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1957-10-24Day | Methylprednisolone | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA011153", "applicant_as_listed_by_fda": "PFIZER", "brand_names": ["MEDROL"], "active_ingredients": ["METHYLPREDNISOLONE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19571024", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |